-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653.O3.6 653. Myeloma: Therapy, excluding Transplantation: Novel Drugs and Combinations

Myeloma: Therapy, excluding Transplantation Program: Oral and Poster Abstracts
Type: Oral
Sunday, December 6, 2015: 4:30 PM-6:00 PM
Hall E1, Level 2 (Orange County Convention Center)
Moderators:
Elena Zamagni, Azienda Ospedaliero-Universitaria and Ravi Vij, MD, MBA, Washington University School of Medicine

Disclosures:
No relevant conflicts of interest to declare.
4:30 PM

James Berenson, MD1, Alan Cartmell2*, Roger Lyons3, Wael Harb4, Dimitrios Tzachanis5*, Richy Agajanian6*, Ralph V. Boccia, MD7, Morton Coleman8, Robert A. Moss, MD9, Robert M. Rifkin10, Marco Schupp11*, Sandra Dixon11*, Ying Ou11*, Janet Anderl11* and Jesus G. Berdeja, MD12

1Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2Comprehensive Blood and Cancer Center, Bakersfield, CA
3US Oncology Research and Cancer Care Centers of South Texas, San Antonio, TX
4Horizon Oncology Center, Lafayette, IN
5Cedars-Sinai Medical Center, Los Angeles, CA
6The Oncology Institute of Hope and Innovation, Downey, CA
7The Center for Cancer and Blood Disorders, Bethesda, MD
8NewYork-Presbyterian/Weill Cornell, New York, NY
9Robert A Moss MD Inc., Fountain Valley, CA
10US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO
11Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA
12Sarah Cannon Research Institute, Nashville, TN

4:45 PM

Karthik Ramasamy1*, Meletios A. Dimopoulos2, Niels W.C.J. van de Donk3, Barbara Gamberi4*, Frank Bridoux5*, Matthew Streetly6, Elisabeth Kueenburg7*, Barbara Rosettani7*, Shona Collins7*, Frederik Lersch7*, Pamela Bacon8*, Katja C. Weisel9* and Pieter Sonneveld, MD, PhD10

1Oxford University Hospitals NHS Trust, Oxford, United Kingdom, Oxford, United Kingdom
2National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
4Arcispedale S. Maria Nuova, Reggio Emilia, Italy
5University Hospital and University of Poitiers, Poitiers, France
6Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, United Kingdom
7Celgene International, Boudry, Switzerland
8Celgene International Sàrl, Boudry, Switzerland
9Hematology & Oncology, Department of Medicine, University Hospital Tuebingen, Tuebingen, Germany
10Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

5:00 PM

Peter M. Voorhees, MD1, Flora Mulkey2*, Hani Hassoun, MD3, Claudia E. Paba-Prada, MD4, Yvonne A. Efebera, MD, MPH5, Eva Hoke2*, Guadalupe Aquino6*, Destin Carlisle7*, Vera Suman8* and Paul G. Richardson, MD9

1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
2Alliance Statistics and Data Center, Durham, NC
3Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY
4Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
5Comprehensive Cancer Center, The Ohio State University, Columbus, OH
6National Institute of Neurological Disorders and Stroke, Office of Clinical Research, NIH, Bethesda, MD
7Alliance Protocol Operations Office, University of Chicago, Chicago, IL
8Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN
9Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

5:15 PM

Jatin J. Shah, MD1, Lei Feng, MS2*, Sheeba K. Thomas, MD3, Donna Weber, MD3, Michael Wang, MD4, Elisabet E. Manasanch, MD3, Kathleen Mendoza, RN3* and Robert Z. Orlowski, Ph.D., M.D.4

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

5:30 PM

Ajai Chari, MD1*, Saurabh Chhabra, MD2*, Saad Usmani, MD3, Sarah Larson, MD4, Ruben Niesvizky, MD5*, Jeffrey Matous, MD6, Cristina Gasparetto, MD7, Beata Holkova, MD8, Matthew Lunning, DO9, Jason Valent, MD10*, Larry D. Anderson Jr., MD, PhD11, Chatchada Karanes, MD12*, Long Kwei, PhD13*, Lipo Chang13*, Thorsten Graef, MD, PhD13*, Elizabeth Bilotti, MSN13* and Kevin McDonagh, MD14*

1Icahn School of Medicine at Mount Sinai, New York, NY
2Medical University of South Carolina, Charleston, SC
3Levine Cancer Institute/Carolinas Healthcare System,, Charlotte, NC
4University of California, Los Angeles, CA
5Weill Cornell Medical College, New York, NY
6Colorado Blood Cancer Institute, Denver, CO
7Duke University Medical Center, Durham, NC
8Virginia Commonwealth University Medical Center, Richmond, VA
9Virginia Commonwealth University Medical Center, Omaha, NE
10Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
11University of Texas Southwestern Medical Center, Dallas, TX
12City of Hope National Medical Center, Duarte, CA
13Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
14Vanderbilt-Ingram Cancer Center, Nashville, TN

5:45 PM

Jatin Shah1*, Ruben Niesvizky, MD2, Edward Stadtmauer3*, Robert M. Rifkin4, James Berenson, MD5, Jesus G. Berdeja, MD6, Jeff P. Sharman, MD7, Roger Lyons8, Zandra Klippel, MD9, Hansen Wong9*, Yu-Lin Chang9* and Saad Usmani10*

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY
3University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
4US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO
5Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
6Sarah Cannon Research Institute, Nashville, TN
7US Oncology Network/Willamette Valley Cancer Institute, Springfield, OR
8US Oncology Research and Cancer Care Centers of South Texas, San Antonio, TX
9Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA
10Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC

*signifies non-member of ASH